Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5208898
Max Phase: Preclinical
Molecular Formula: C19H18BrN7O2
Molecular Weight: 456.30
Associated Items:
ID: ALA5208898
Max Phase: Preclinical
Molecular Formula: C19H18BrN7O2
Molecular Weight: 456.30
Associated Items:
Canonical SMILES: COCCNC(=O)CNc1ncc2c(Br)nn(-c3ccc4ncccc4c3)c2n1
Standard InChI: InChI=1S/C19H18BrN7O2/c1-29-8-7-22-16(28)11-24-19-23-10-14-17(20)26-27(18(14)25-19)13-4-5-15-12(9-13)3-2-6-21-15/h2-6,9-10H,7-8,11H2,1H3,(H,22,28)(H,23,24,25)
Standard InChI Key: GLGRHNQCUGPWAB-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 456.30 | Molecular Weight (Monoisotopic): 455.0705 | AlogP: 2.30 | #Rotatable Bonds: 7 |
Polar Surface Area: 106.85 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 11.97 | CX Basic pKa: 4.66 | CX LogP: 1.65 | CX LogD: 1.65 |
Aromatic Rings: 4 | Heavy Atoms: 29 | QED Weighted: 0.41 | Np Likeness Score: -2.02 |
1. Jackson JJ, Shibuya GM, Ravishankar B, Adusumilli L, Bradford D, Brockstedt DG, Bucher C, Bui M, Cho C, Colas C, Cutler G, Dukes A, Han X, Hu DX, Jacobson S, Kassner PD, Katibah GE, Ko MYM, Kolhatkar U, Leger PR, Ma A, Marshall L, Maung J, Ng AA, Okano A, Pookot D, Poon D, Ramana C, Reilly MK, Robles O, Schwarz JB, Shakhmin AA, Shunatona HP, Sreenivasan R, Tivitmahaisoon P, Xu M, Zaw T, Wustrow DJ, Zibinsky M.. (2022) Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis Therapy., 65 (19.0): [PMID:36127295] [10.1021/acs.jmedchem.2c00736] |
Source(1):